These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 943554

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Phase I trial of dianhydrogalactitol administered Iv in a weekly schedule.
    Vogel CL, Winton EF, Moore MR, Sohner S.
    Cancer Treat Rep; 1976 Jul; 60(7):895-901. PubMed ID: 795538
    [Abstract] [Full Text] [Related]

  • 4. Phase II studies of dianhydrogalactitol and VP-16-213 in colorectal cancer.
    Perry MC, Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG.
    Cancer Treat Rep; 1976 Sep; 60(9):1247-50. PubMed ID: 797447
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
    Wolff I, Bench K, Beijnen JH, Bruntsch U, Cavalli F, de Jong J, Groot Y, van Tellingen O, Wanders J, Sessa C.
    Clin Cancer Res; 1996 Oct; 2(10):1717-23. PubMed ID: 9816122
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of dibromodulcitol (NSC-104800).
    Andrews NC, Weiss AJ, Ansfield FJ, Rochlin DB, Mason JH.
    Cancer Chemother Rep; 1971 Feb; 55(1):61-5. PubMed ID: 5121653
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study.
    Thigpen JT, Al-Sarraf M, Hewlett JS.
    Cancer Treat Rep; 1979 Apr; 63(4):525-8. PubMed ID: 445506
    [Abstract] [Full Text] [Related]

  • 12. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
    Sigman LM, Van Echo DA, Egorin MJ, Whitacre MY, Aisner J.
    Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
    [Abstract] [Full Text] [Related]

  • 13. Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
    Arteaga CL, Brown TD, Kuhn JG, Shen HS, O'Rourke TJ, Beougher K, Brentzel HJ, Von Hoff DD, Weiss GR.
    Cancer Res; 1989 Aug 15; 49(16):4648-53. PubMed ID: 2743343
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of cis-dichloro-trans-dihydroxy-bis(isopropylamine)platinum IV (CHIP).
    Ribaud P, Gouveia J, Misset JL, Mathé G.
    Oncology; 1986 Aug 15; 43(2):78-82. PubMed ID: 3951788
    [Abstract] [Full Text] [Related]

  • 15. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
    Egorin MJ, Sigman LM, Van Echo DA, Forrest A, Whitacre MY, Aisner J.
    Cancer Res; 1987 Jan 15; 47(2):617-23. PubMed ID: 3791246
    [Abstract] [Full Text] [Related]

  • 16. Early clinical study of an intermittent schedule for maytansine (NSC-153858): brief communication.
    Eagan RT, Ingle JN, Rubin J, Frytak S, Moertel CG.
    J Natl Cancer Inst; 1978 Jan 15; 60(1):93-6. PubMed ID: 628025
    [Abstract] [Full Text] [Related]

  • 17. Phase I clinical and pharmacological study of merbarone.
    Dimaggio JJ, Warrell RP, Muindi J, Stevens YW, Lee SJ, Lowenthal DA, Haines I, Walsh TD, Baltzer L, Yaldaei S.
    Cancer Res; 1990 Feb 15; 50(4):1151-5. PubMed ID: 2297763
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
    Tan CT, Hancock CH, Mondora A, Hoffman NW.
    Cancer Res; 1984 Feb 15; 44(2):831-5. PubMed ID: 6692381
    [Abstract] [Full Text] [Related]

  • 19. Clinical and pharmacologic evaluation of split-dose intermittent therapy with dianhydrogalactitol.
    Eagan RT, Ames MM, Powis G, Kovach JS.
    Cancer Treat Rep; 1982 Feb 15; 66(2):283-7. PubMed ID: 7034934
    [Abstract] [Full Text] [Related]

  • 20. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
    Valdivieso M, Bedikian AY, Burgess MA, Savaraj N, Jeffers WB, Bodey GP.
    Cancer Treat Rep; 1981 Feb 15; 65(9-10):841-4. PubMed ID: 7273017
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.